RGEN · Repligen Corporation — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on RGEN. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About RGEN · Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Live Quote
SELL (score -3) · 12-1 mom -8.1% · RSI 52.2 · above_50_only · -26.6% from high
Targets blend Wall Street consensus (19 analysts: low $142.00 / mean $176.11 / high $220.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Anti-signal gate triggered for convertible dilution (>10% of float). The 'accounting' flag refers to non-cash divestiture/restructuring charges, not irregularities, but the dilution overhang ($546M notes) combined with severely stretched valuation (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield) and zero insider buying makes this a skip. No margin of safety exists for equity or income structures.
Anti-signal gate triggered for convertible dilution (>10% of float). The 'accounting' flag refers to non-cash divestiture/restructuring charges, not irregularities, but the dilution overhang ($546M notes) combined with severely stretched valuation (49.7x Fwd P/E, 52x EV/EBITDA, <1% FCF yield) and zero insider buying makes this a skip. No margin of safety exists for equity or income structures.
Repligen is a life sciences bioprocessing tools company with ~$760M TTM revenue growing at ~15% organically. Q1 2026 delivered a +22.9% EPS surprise (beat by $0.09), with 50%+ analytics growth and strong China demand. The stock has been under severe pressure — down ~28% from its January 2026 high of $175.77 to current ~$126 — driven by multiple concerns: tariff uncertainty on biopharma equipment, customer concentration risk, and decelerating monoclonal antibody market growth. However, forward P/E of ~49.7x is expensive for a company with only 8.9% operating margin and 6.7% net margin, leaving limited upside without significant margin expansion. The CEO's tight vote (Karen Dawes/Carrie Eglinton Manner narrowly approved) and Glenn Muir's significant opposition (~25% against) signal governance tension. No open-market insider buys in the past 90 days — all recent Form 4s are equity compensation grants. The stock is below its 200-day MA, creating technical headwinds despite a recent MACD bullish cross.
Rich valuation (40x FPE, 42x EV/EBITDA) and broken technicals negate any income strategy edge. Material insider selling, convertible dilution overhang, and customer concentration trigger anti-signal gates, leaving no defensible entry point.
Repligen is a bioprocessing tools company (filtration, chromatography, analytics) that has been under significant pressure — down ~41% from its 52-week high of $175.77 and now near the low at $102.87. Q1 FY26 was a solid beat (+23% EPS surprise), full-year guidance raised to $1.97-$2.05 adjusted EPS, yet the stock has continued lower on broad sector rotation and valuation concerns. The forward P/E ~40x is rich vs. sector medians of 25-30x; EV/EBITDA ~42.5x is elevated for a tools name growing at mid-teens rates with 53% gross margins. Insiders are net sellers (CEO Loeillot sold ~$536K via pre-arranged 10b5-1 plan in April; director Muir exercised options and likely sold). No open-market purchase cluster exists. The stock sits well below both its 50-day ($118.81) and 200-day ($137.87) moving averages with RSI at 32.3 (oversold) but no reversal confirmation yet. IV is elevated (~52-62% ATM), making income strategies viable if the Analyst wants to play a range-bound bounce.